Product news

Share this article:
Novartis and Medicines for Malaria Venture have launched a new pediatric formulation of the malaria treatment Coartem. The product, Coartem Dispersible, is the first artemisinin-based combination therapy (ACT) developed specifically for children, according to a company statement. Novartis will offer the product without profit for public sector use in malaria-endemic regions of Africa.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.